It has been emphasized frequently that Bertolt Brecht’s political theater, Die Maßnahme in particular, has been influenced by Carl Schmitt’s theory of the sovereign and the state of exception. While it is indeed remarkable that his learning play seems to record some of the concepts which in Schmitt belong to the categories of political theory, this essay will return to the role and discourse of the theater in Brecht. The drama of revolution is a political text through and through, but it cannot separate the political from the theater; the drama of revolution is in search of a form, a meta-theater, in which the overcoming of an order is thus first and foremost the attempt to suspend the law of genre. Strikingly, Brecht’s learning play brings to the stage all the characteristics which have, since Aristotle, marked tragedy: the pity, the error of a hero, the hero’s comprehension of the error, the guilt of an innocent man, the hero’s death, the sacrifice, and catharsis. Brecht reproduces the law of the genre he wishes to supersede and entangles his figures in inescapable aporias which have dominated the meta-discourse on drama in revolutionary theater from Büchner’s Danton’s Tod to Heiner Müller’s Mauser. ; Germanic Languages and Literatures
Acknowledgments -- Portfolio theory and management : an overview / H. Kent Baker and Greg Filbeck -- Portfolio theory and asset pricing -- Modern portfolio theory / Eric Jacquier -- Asset pricing theories, models, and tests / Nikolay Gospodinov and Cesare Robotti -- Asset pricing and behavioral finance / Hersh Shefrin -- The investment policy statement and fiduciary duties -- Assessing risk tolerance / Sherman D. Hanna, Michael A. Guillemette, and Michael S. Finke -- Private wealth management / Dianna Preece -- Institutional wealth management / Eric J. Robbins -- Fiduciary duties and responsibilities of portfolio managers / Remus D. Valsan and Moin A. Yahya -- Asset allocation and portfolio construction -- The role of asset allocation in the investment decision-making process/ james l. farrell, jr -- Asset allocation models / J. Clay Singleton -- Preference models in portfolio construction and evaluation / Massimo Guidolin -- Portfolio construction with downside risk / Harald Lohre, Thorsten Neumann, and Thomas Winterfeldt -- Asset allocation with downside risk management / Joshua M. Davis and Sebastien Page -- Alternative investments / Lars Helge Hass, Denis Schweizer, Juliane Proelss -- Risk management -- Measuring and managing market risk / Christoph Kaserer -- Measuring and managing credit and other risks / Gabriele Sabato -- Portfolio execution, monitoring, and rebalancing -- Trading strategies, portfolio monitoring, and rebalancing / Ricardo Cesari and Massimiliano Marzo -- Effective trade execution / Ricardo Cesari, Massimiliano Marzo, and Paolo Zagalia -- Market timing methods and results / Panagiotis Schizas -- Evaluating and reporting portfolio performance -- Evaluating portfolio performance : reconciling asset selection and market timing / Arnaud Cavé, Georges Hübner, and Thomas Lejeune -- Benchmarking / Abraham Lioui and Patrice Poncet -- Attribution analysis / Nanne Brunia and Auke Plantinga -- Equity investment styles / Andrew Mason -- Use of derivatives / Matthieu Leblanc -- Performance presentation / Timothy P. Ryan -- Special topics -- Exchange traded funds: the success story of the last two decades / Gerasimos G. Rompotis -- The past, present, and future of hedge funds / Roland Füss and Sarah Müller -- Portfolio and risk management for private equity fund investments / Niklas Wagner and Axel Buchner -- Venture capital / Paschal Gantenbein, Reto Forrer, and Nils Herold -- Socially responsible investing / Hunter Holzhauer
The only way to cure leukemia is by cooperative research. To optimize research, the European LeukemiaNet integrates 105 national leukemia trial groups and networks, 105 interdisciplinary partner groups and about 1,000 leukemia specialists from 175 institutions. They care for tens of thousands of leukemia patients in 33 countries across Europe. Their ultimate goal is to cure leukemia. Since its inception in 2002, the European LeukemiaNet has steadily expanded and has unified leukemia research across Europe. The European LeukemiaNet grew from two major roots: 1) the German Competence Network on Acute and Chronic Leukemias; and 2) the collaboration of European Investigators on Chronic Myeloid Leukemia. The European LeukemiaNet has improved leukemia research and management across Europe. Its concept has led to funding by the European Commission as a network of excellence. Other sources (European Science Foundation; European LeukemiaNet-Foundation) will take over when the support of the European Commission ends.